CDC reports address COVID-19 Rebound

The Centers for Disease Control and Prevention (CDC) has recently issued two reports in the Morbidity and Mortality Weekly Report (MMWR) discussing the connection between receiving antiviral treatment and the occurrence of COVID-19 rebound. According to these studies, COVID-19 rebound can occur regardless of whether a patient undergoes antiviral treatment or not.
The rebound phenomenon appears to be a manifestation of natural fluctuations in the COVID-19 virus during the early stages of the illness. Several factors may contribute to an individual's likelihood of experiencing rebound, including factors like immunosuppression, delayed viral clearance, and their overall immune response. Importantly, the use of the antiviral medication Paxlovid was not found to be linked to rebound.
In light of these findings, the CDC's conclusion is that the benefits of COVID-19 antiviral treatment in terms of reducing the risk of severe illness, hospitalization, and death outweigh any potential risk associated with viral rebound.
Staff contact;